AUROPHARMA Share price chart 25 Apr 2025 :-37.70(-3.00%) *Stock prices shown are delayed by 5 minutes Key Indicators Data as per latest reports and statements Today's low/high₹1,210.00 / ₹1,268.90 52-week low/high₹1,010 / ₹1,592 ...
Ltd. obtained the general distribution rights in Mainland China for the anti-influenza drug from Natco Pharma Limited ("Natco"). The first batch of cargo has arrived at the port in Chongqing City, and the drug will be introduced to the market for domestic treatment and prevention of Type A...
6.3.5 Natco Foods 6.3.6 Coopeniox 6.3.7 Proventus Retail Private Limited 6.3.8 Diamond Foods, LLC 6.3.9 Plantabul Ltd 6.3.10 Karamhans Foods Pvt. Ltd. *List Not Exhaustive 7. MARKET OPPORTUNITIES AND FUTURE TRENDS 8. IMPACT OF COVID-19 ON THE MARKET ...
The essential antiviral drugs get regulatory approval while also lowering financial risks as a result of these strategic collaborations that promote increased drug availability. F. Hoffmann-La Roche Ltd., NATCO Pharma Limited, Teva Pharmaceutical Industries Ltd, LUPIN Limited, Amneal pharmaceuticals LLC,...
Also, the increasing adoption of remote patient monitoring for cancer treatment in this region is expected to drive the growth of the studied segment. For instance, in September 2022 NATCO cancer center, Government General hospital installed Dozee's contactless remote patient monitoring and...
In March 2022, Natco Pharma announced the launch of the first generic version of Celgene's top-selling cancer medicine Revlimid (lenalidomide capsules) in the United States market with its marketing partner Arrow International, an affiliate of Israeli pharma maker Teva Pharmaceutical Industries. ...